Theriva Biologics (TOVX) Other Non-Current Liabilities (2014 - 2026)
Theriva Biologics (TOVX) posted quarterly Other Non-Current Liabilities of $8.8 million for Q1 2026, up 55.46% year-over-year from $5.7 million in Q1 2025, and down 11.66% quarter-over-quarter from $10.0 million in Q4 2025.
Theriva Biologics (TOVX) Other Non-Current Liabilities (2014 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Other Non-Current Liabilities for 10 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 55.46% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $8.8 million (up 55.46% YoY), while the FY2025 annual figure was $10.0 million, up 43.47% from the prior year.
- Other Non-Current Liabilities fell to $8.8 million in Q1 2026 per TOVX's latest filing, from $10.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $11.1 million in Q1 2022 and bottomed at $2.2 million in Q2 2022.
- Historically, Other Non-Current Liabilities has averaged $6.9 million across 5 years, with a median of $6.5 million in 2024.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 165.31% in 2023 and fell as far as 51.28% in 2023.
- Theriva Biologics' Other Non-Current Liabilities stood at $7.2 million in 2022, then fell by 12.99% to $6.3 million in 2023, then rose by 11.14% to $7.0 million in 2024, then jumped by 43.47% to $10.0 million in 2025, then fell by 11.66% to $8.8 million in 2026.
- Business Quant data shows TOVX's Other Non-Current Liabilities at $8.8 million in Q1 2026, $10.0 million in Q4 2025, and $10.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.17 Mn |
| Mar 31, 2026 | 8.84 Mn |
| Dec 31, 2025 | 10.00 Mn |
| Sep 30, 2025 | 10.79 Mn |
| Jun 30, 2025 | 10.16 Mn |
| Mar 31, 2025 | 5.69 Mn |
| Dec 31, 2024 | 6.97 Mn |
| Sep 30, 2024 | 6.79 Mn |
| Jun 30, 2024 | 6.20 Mn |
| Mar 31, 2024 | 6.48 Mn |
| Dec 31, 2023 | 6.27 Mn |
| Sep 30, 2023 | 5.94 Mn |
| Jun 30, 2023 | 5.77 Mn |
| Mar 31, 2023 | 5.41 Mn |
| Dec 31, 2022 | 7.21 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 2.20 Mn |
| Mar 31, 2022 | 11.10 Mn |
| Sep 30, 2018 | 19,000.00 |
| Jun 30, 2018 | 645,000.00 |